Kirsten rat sarcoma G12C inhibitor treatment for a patient with relapsed metastatic lung adenocarcinoma: A case report

Figure 1 Contrast-enhanced computed tomography images. A-E: Lung window; A: The images show the local nodular thickening of the right pleura; B: The mass film shadow near the right lung portal; C: The images show the pleural effusion; D: The images show the cervical lymph nodes metastasis; E: Coronal observation shows that the mediastinal lymph nodes are enlarged; F-J: Mediastinal window; F: The images show the local nodular thickening of the right pleura; G: The mass film shadow near the right lung portal; H: The images show the pleural effusion; I: The images show the cervical lymph nodes metastasis; J: Coronal observation shows that the mediastinal lymph nodes are enlarged.

Figure 2 Treatment course of the patient with lung adenocarcinoma. PD: Progressive disease; PFS: Progression-free survival; KRAS G12C: Kirsten rat sarcoma viral oncogene homolog at glycine 12 to cysteine.

Figure 3 Representative radiologic images of the patient before and after the Kirsten rat sarcoma viral oncogene homolog at glycine 12 to cysteine inhibitor. A-E: May 31, 2023; F-J: July 25, 2023.

Figure 4 Enhanced computed tomography showed the follow-up of the left diaphragmatic angle lymph node. A: On May 31, 2023; B: On May 7, 2024; C: On July 10, 2024; D: On September 11, 2024; E: On November 11, 2024. The orange arrows in the figures point to the metastatic left diaphragmatic angle lymph node.